Research programme: amyotrophic lateral sclerosis gene therapy - Janus/Ferrer/Bioingenium

Drug Profile

Research programme: amyotrophic lateral sclerosis gene therapy - Janus/Ferrer/Bioingenium

Latest Information Update: 12 Mar 2014

Price : $50

At a glance

  • Originator Universitat Autonoma de Barcelona; University of Zaragoza
  • Developer BioIngenium; Ferrer; Janus Developments
  • Class Gene therapies
  • Mechanism of Action Apoptosis inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 12 Mar 2014 Preclinical development is ongoing in Spain
  • 16 Nov 2010 Preclinical trials in Amyotrophic lateral sclerosis in Spain (IM)
  • 16 Nov 2010 Janus Developments, Ferrer and Bioingenium collaborate to develop tetanus toxin fragment gene therapy for Amyotrophic lateral sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top